Shariaportfolio Inc. Buys 1,858 Shares of Johnson & Johnson (NYSE:JNJ)

Shariaportfolio Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 12.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,513 shares of the company’s stock after purchasing an additional 1,858 shares during the period. Johnson & Johnson makes up about 1.3% of Shariaportfolio Inc.’s investment portfolio, making the stock its 13th biggest position. Shariaportfolio Inc.’s holdings in Johnson & Johnson were worth $2,414,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Blair William & Co. IL boosted its stake in Johnson & Johnson by 12.3% during the 2nd quarter. Blair William & Co. IL now owns 1,045,546 shares of the company’s stock worth $152,817,000 after acquiring an additional 114,780 shares during the last quarter. O Brien Greene & Co. Inc lifted its holdings in shares of Johnson & Johnson by 9.1% in the second quarter. O Brien Greene & Co. Inc now owns 9,567 shares of the company’s stock valued at $1,398,000 after purchasing an additional 797 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its stake in shares of Johnson & Johnson by 6.6% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 135,526 shares of the company’s stock worth $19,808,000 after acquiring an additional 8,408 shares in the last quarter. Argent Trust Co increased its stake in Johnson & Johnson by 0.5% in the 2nd quarter. Argent Trust Co now owns 189,595 shares of the company’s stock valued at $27,711,000 after buying an additional 963 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its position in shares of Johnson & Johnson by 3.9% in the second quarter. Mercer Global Advisors Inc. ADV now owns 695,805 shares of the company’s stock valued at $92,799,000 after acquiring an additional 26,174 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. Morgan Stanley increased their price target on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. TD Securities cut their target price on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. TD Cowen cut their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $167.07 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The stock has a market capitalization of $402.08 billion, a PE ratio of 10.42, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The firm’s 50 day moving average price is $160.38 and its 200-day moving average price is $154.01.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the prior year, the firm posted $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 4.3% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.